Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cara Therapeutics (NQ: CARA ) 0.3348 +0.0098 (+3.02%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cara Therapeutics < Previous 1 2 Next > Cara Therapeutics Announces Exploration of Strategic Alternatives July 11, 2024 Piper Sandler & Co. to act as financial advisor From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica June 12, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Reports First Quarter 2024 Financial Results May 13, 2024 Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 May 06, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 March 07, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results March 04, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 February 12, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 January 22, 2024 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis December 18, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Reports Third Quarter 2023 Financial Results November 13, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty November 02, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023 October 23, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients September 25, 2023 Approval triggers $1.5 million milestone payment to Cara From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain September 15, 2023 Via Investor Brand Network Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Reports Second Quarter 2023 Financial Results August 07, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors August 03, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference August 02, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 July 24, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Present at the Jefferies Healthcare Conference June 01, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus May 18, 2023 Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Reports First Quarter 2023 Financial Results May 15, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023 May 01, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference April 10, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report March 14, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results March 06, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 February 21, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine February 08, 2023 Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment From Cara Therapeutics, Inc. Via GlobeNewswire Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023 January 17, 2023 From Cara Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.